Beyond the binding site: PROTAC-mediated protein degradation assists the therapeutic paradigm of hematological malignancies.
Hematological malignancies represent a growing global health burden, with conventional therapies limited by systemic toxicity and resistance mechanisms. Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that hijack cellular degradation machinery to eliminate, rather than merely inhibit, target p...